{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:42:39Z","timestamp":1759405359034,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21nf0101626"],"award-info":[{"award-number":["JP21nf0101626"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vaccine.2022.12.025","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T01:07:39Z","timestamp":1671152859000},"page":"1834-1847","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Results from a preclinical study in rodents and a Phase 1\/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults"],"prefix":"10.1016","volume":"41","author":[{"given":"Takuhiro","family":"Sonoyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Shinkai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Iwata-Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Shiwa-Sudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Hemmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ainai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyo","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Omoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Yokokawa Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Ariyasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.12.025_b0005","unstructured":"World Health Organization. WHO coronavirus (COVID-19) dashboard. Available from: https:\/\/covid19.who.int Last accessed: May 9, 2022."},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.025_b0010","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1002\/jmv.27590","article-title":"Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety","volume":"94","author":"Meng","year":"2022","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.025_b0015","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/s41467-022-29219-2","article-title":"Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates","volume":"13","author":"Pavot","year":"2022","journal-title":"Nature Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.025_b0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3201\/eid2701.203515","article-title":"Waning antibody responses in asymptomatic and symptomatic SARS-CoV-2 infection","volume":"27","author":"Choe","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"31","key":"10.1016\/j.vaccine.2022.12.025_b0025","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1016\/j.vaccine.2022.05.081","article-title":"Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys","volume":"40","author":"Hashimoto","year":"2022","journal-title":"Vaccine"},{"issue":"27","key":"10.1016\/j.vaccine.2022.12.025_b0030","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1016\/j.vaccine.2022.04.054","article-title":"Phase 1\/2 clinical trial of COVID-19 vaccine in Japanese participants: a report of interim findings","volume":"40","author":"Iwata","year":"2022","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2022.12.025_b0035","article-title":"Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2\/3, randomized, observer-blinded, noninferiority study","volume":"S0264\u2013410X","author":"Kamitani","year":"2022","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.12.025_b0040","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrd3203","article-title":"Targeting toll-like receptors: emerging therapeutics?","volume":"9","author":"Hennessy","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.vaccine.2022.12.025_b0045","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/jvi.66.12.7444-7451.1992","article-title":"Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB\/c mice is abrogated by depletion of CD4+ T cells","volume":"66","author":"Connors","year":"1992","journal-title":"J Virol"},{"issue":"8","key":"10.1016\/j.vaccine.2022.12.025_b0050","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1128\/jvi.68.8.5321-5325.1994","article-title":"Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB\/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10","volume":"68","author":"Connors","year":"1994","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.025_b0055","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nm.1894","article-title":"Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease","volume":"15","author":"Delgado","year":"2009","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.025_b0060","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/JVI.02980-14","article-title":"Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology","volume":"89","author":"Honda-Okubo","year":"2015","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2022.12.025_b0065","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","article-title":"Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus","volume":"12","author":"Agrawal","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"13","key":"10.1016\/j.vaccine.2022.12.025_b0070","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2022.12.025_b0075","article-title":"A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection","volume":"8(1):eabh3827","author":"Iwata-Yoshikawa","year":"2022","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.025_b0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/1348-0421.12754","article-title":"Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs","volume":"64","author":"Sekimukai","year":"2020","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2022.12.025_b0085","unstructured":"WMA Declaration of Helsinki \u2013 Ethical principles for medical research involving human subjects. Available from: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/ Last accessed: March 9, 2022."},{"key":"10.1016\/j.vaccine.2022.12.025_b0090","unstructured":"International Council for Harmonisation. Efficacy guidelines. Available from: https:\/\/www.ich.org\/page\/efficacy-guidelines Last accessed: March 9, 2022."},{"key":"10.1016\/j.vaccine.2022.12.025_b0095","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.025_b0100","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S2666-5247(21)00025-2","article-title":"Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study","volume":"2","author":"Chia","year":"2021","journal-title":"Lancet Microbe"},{"issue":"7830","key":"10.1016\/j.vaccine.2022.12.025_b0105","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"Van Doremalen","year":"2020","journal-title":"Nature"},{"issue":"7830","key":"10.1016\/j.vaccine.2022.12.025_b0110","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.025_b0115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41541-021-00311-w","article-title":"mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents","volume":"6","author":"Rauch","year":"2021","journal-title":"NPJ Vac"},{"issue":"3","key":"10.1016\/j.vaccine.2022.12.025_b0120","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1213\/00000539-199909000-00064","article-title":"The importance of dose-response in study design","volume":"89","author":"Shafer","year":"1999","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1016\/j.vaccine.2022.12.025_b0125","doi-asserted-by":"crossref","first-page":"e35421","DOI":"10.1371\/journal.pone.0035421","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.vaccine.2022.12.025_b0130","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2022.12.025_b0135","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.1038\/s41467-021-27316-2","article-title":"A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults","volume":"12","author":"Haranaka","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2022.12.025_b0140","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.12.025_b0145","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.12.025_b0150","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.12.025_b0155","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2022.12.025_b0160","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1513\/pats.200701-021AW","article-title":"Antiinfective applications of Toll-like receptor 9 agonists","volume":"4","author":"Krieg","year":"2007","journal-title":"Proc Am Thorac Soc"},{"issue":"48","key":"10.1016\/j.vaccine.2022.12.025_b0165","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1016\/j.vaccine.2021.10.066","article-title":"Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum\/CpG adjuvants","volume":"39","author":"Liu","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.025_b0170","unstructured":"National Institute of Health. U.S. National Library of Medicine. Phase I clinical trial of recombinant SARS-CoV-2 spike protein vaccine (CHO cell). ClinicalTrials.gov Identifier: NCT04982068 Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04982068 Last accessed: March 9, 2022."},{"key":"10.1016\/j.vaccine.2022.12.025_b0175","unstructured":"National Institute of Health. U.S. National Library of Medicine. Phase II clinical trial of recombinant SARS-CoV-2 spike protein vaccine (CHO cell). ClinicalTrials.gov Identifier: NCT04990544 Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04990544 Last accessed: March 9, 2022."},{"key":"10.1016\/j.vaccine.2022.12.025_b0180","unstructured":"National Institute of Allergy and Infectious Diseases. The important role of animal research in mRNA COVID-19 vaccine development. Available from: https:\/\/www.niaid.nih.gov\/news-events\/role-animal-research-mrna-covid-19-vaccine-development Last accessed: March 9, 2022."},{"key":"10.1016\/j.vaccine.2022.12.025_b0185","unstructured":"Forum on Neuroscience and Nervous System Disorders; Board on Health Sciences Policy; Institute of Medicine. Improving and accelerating therapeutic development for nervous system disorders: workshop summary. Washington (DC): National Academies Press (US); 2014 Feb 6. 2, Drug Development Challenges. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK195047\/ Last accessed: March 9, 2022."},{"key":"10.1016\/j.vaccine.2022.12.025_b0190","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41231-019-0050-7","article-title":"Lost in translation: the valley of death across preclinical and clinical divide \u2013 identification of problems and overcoming obstacles","volume":"4","author":"Seyhan","year":"2019","journal-title":"Transl Med Commun"},{"issue":"4","key":"10.1016\/j.vaccine.2022.12.025_b0195","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.coi.2008.07.007","article-title":"Accessing the therapeutic potential of immunostimulatory nucleic acids","volume":"20","author":"Barchet","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2022.12.025_b0200","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12967-017-1152-5","article-title":"Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic applications","volume":"15","author":"Bai","year":"2017","journal-title":"J Transl Med"},{"issue":"3","key":"10.1016\/j.vaccine.2022.12.025_b0205","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1586\/14760584.8.3.293","article-title":"Olesen O.F. Vaccine adjuvants: scientific challenges and strategic initiatives","volume":"8","author":"Harandi","year":"2009","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.025_b0210","doi-asserted-by":"crossref","first-page":"20861","DOI":"10.1038\/s41598-022-25418-5","article-title":"Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice","volume":"12","author":"Homma","year":"2022","journal-title":"Sci Rep"},{"issue":"10275","key":"10.1016\/j.vaccine.2022.12.025_b0215","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","article-title":"Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Richmond","year":"2021","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:24:15Z","timestamp":1759404255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22015407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0264410X22015407"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results from a preclinical study in rodents and a Phase 1\/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}